LI
Lixte Biotechnology Holdings, Inc.
LIXTW · NASDAQ
$0.02 +4.74% (+$0.00)
Market Cap $100.6K
P/E Ratio -
Div. Yield -
ROE 219.02%
Bulios Fair Price
$0.03
35.7% upside
Current Price
$0.022
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LIXTW is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 0.02x
PEG N/A
P/E N/A
Growth
100 /100
Growing Book val. growth 28.50%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 76.08%
ROIC 79.31%
Asset turnover 0.00x
Debt
79 /100
Low Int. coverage -419.32x
Debt/Equity 0.00x
Net debt/EBITDA 0.66x
Stability
55 /100
Moderate Profitable years 0
Beta 0.89x
EPS volatility 46.59%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LIXTW
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Geordan G. Pursglove
Employees
2
Headquarters
Pasadena